Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SinoMab BioScienceFRA:4VF 19 EV-to-OCF is -19.57 as of Sep. 10, 2026. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,404 Biotechnology companies, SinoMab BioScience ranks better than 81.27% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SinoMab BioScience's Enterprise Value is €178.34 Mil.
SinoMab BioScience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.11 Mil. Therefore, SinoMab BioScience's EV-to-OCF for today is -19.57.
The historical rank and industry rank for SinoMab BioScience's EV-to-OCF or its related term are showing as below:
FRA:4VF'
s EV-to-OCF Range Over the Past 10 Years
Min: -30.01 Med: -11.14 Max: -4.07
Current: -20.16
During the past 9 years, the highest EV-to-OCF of SinoMab BioScience was -4.07. The lowest was -30.01. And the median was -11.14.
FRA:4VF's EV-to-OCF is ranked better than 81.27% of 1404
companies
in the Biotechnology industry
Industry Median: -3.45
vs FRA:4VF: -20.16
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SinoMab BioScience's PE Ratio (TTM) for today is calculated as:
SinoMab BioScience's share price for today is €0.117.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.017.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SinoMab BioScience EV-to-OCF Related Terms
SinoMab BioScience EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SinoMab BioScience's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SinoMab BioScience's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SinoMab BioScience EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SinoMab BioScience's EV-to-OCF falls into.
SinoMab BioScience's current Enterprise Value is €178.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SinoMab BioScience (FRA:4VF) has a EV-to-OCF of -19.57 as of Sep. 10, 2026. According to the industry distribution chart, SinoMab BioScience ranks #263 out of 1404 companies in the Biotechnology industry, placing it in the top 18.7%.
Is SinoMab BioScience's EV-to-OCF too high?
SinoMab BioScience's current EV-to-OCF is -19.57. Based on the distribution chart, SinoMab BioScience ranks #263 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #263 out of 1404 companies for EV-to-OCF. This places SinoMab BioScience in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SinoMab BioScience's current EV-to-OCF is -19.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current EV-to-OCF of -19.57. The current EV-to-OCF is -19.57. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current EV-to-OCF is -19.57 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score
Get the complete analysis for FRA:4VF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4VF has been successfully added to your 
